Provided by NATAP
AASLD: Safety of Ribavirin-containing Regimens of ABT-450/r, ABT-333, and ABT-267 for the Treatment of HCV Genotype 1 Infection and Efficacy in Subjects With Ribavirin Dose Reductions - (11/06/13)
AASLD: High Medication Adherence in HCV-Infected Patients Taking a Triple-DAA Regimen for 12 Weeks - (11/06/13)
AASLD: Interferon- and Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-naïve Patients and Prior Null Responders - (11/04/13)
64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013
No comments:
Post a Comment